• Male or female, ≥ 20 years and ≤ 80 years of age.

• Patients with clinically confirmed primary HCC following American Association for the Study of Liver Diseases (AASLD, Appendix 1) guidance:

‣ Cyto-histological evidence, or

⁃ Coincident imaging evidence using computerized tomography (CT) or magnetic resonance imaging (MRI)

• Based on investigator discretion, patients who are diagnosed at Barcelona Clinic Liver Cancer (BCLC) stage B and are ineffective or unsuitable for resection, immediate liver transplantation, Trans Arterial Chemoembolization (TACE), or current local ablative treatment and meet all of the following conditions at study entry:

‣ Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 1.

⁃ Child Pugh score class A or B.

• Patients with at least one measurable lesion with size ≥ 1 cm.

• Patients with cumulative total treated tumor volume ≤ 366 cm3 and ≤ 4 target tumors.

• Patients with adequate bone marrow, liver and renal function within 28 days prior to study entry, as defined by the following:

‣ Hemoglobin \> 10.0 g/dl.

⁃ Absolute neutrophil count (ANC) \> 1,500/mm3.

⁃ Platelet count \> 80k/mm3 correctable by component therapy.

⁃ Albumin ≥ 3 g/dl.

⁃ Total bilirubin \< 2 mg/dL.

⁃ Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) \< 5 x upper normal limit (UNL).

⁃ Blood urea nitrogen (BUN) and serum creatinine \< 1.5 x UNL.

⁃ International normalized ratio (INR) \< 1.5 or prothrombin time (PT) \< 15 seconds.

• Patients with life expectancy \> 3 months as judged by investigator.

• Patients who understand and comply to the study procedure and be willing to provide a written informed consent form.